A phase I study of MM-302, a HER2-targeted liposomal doxorubicin, in patients with advanced, HER2-positive (HER2+) breast cancer

被引：0

作者：

Munster, Pamela N.

Miller, Kathy

Krop, Ian E.

Dhindsa, Navreet

Reynolds, Joe

Geretti, Elena

Niyikiza, Clet

Nielsen, Ulrik

Hendriks, Bart

Wickham, Thomas J.

Moyo, Victor M.

LoRusso, Patricia

机构：

[1] Univ Calif San Francisco, San Francisco Helen Diller Family Comprehens Canc, San Francisco, CA 94143 USA

[2] Indiana Univ, Simon Canc Ctr, Indianapolis, IN 46204 USA

[3] Dana Farber Canc Inst, Boston, MA 02115 USA

[4] Merrimack Pharmaceut, Cambridge, MA USA

[5] Karmanos Canc Inst, Detroit, MI USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS663

引用

页数：1